Glycopegylated erythropoietin formulations

US7842661B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Shawn DeFrees · North Wales, US
• Robert J. Bayer · San Diego, US
• David A. Zopf · Strafford, US
• Jichao Kang · Ann Arbor, US
• Walter S. Willett · Doylestown, US

Key dates

• Filing date: May 25, 2006
• Grant date: Nov 30, 2010
• Expiry date: May 25, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.